SecBot SecBot
144 ·Filed Apr 8, 2026

IMCR

Immunocore Holdings plc
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001974494-26-000149
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider transaction by a non-executive affiliate; traders should monitor for actual execution but no immediate price impact is expected. The sale represents a small fraction of the company's $1.5B market cap and does not signal material concern.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.85
T+0 close · Apr 8, 2026 · via day close
Latest settled
+2.04%
T+60 · $32.50
Vs SPY
−8.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $31.85entry
  2. T+1 · 7mo ago −0.13%α −0.70% · $31.81
  3. T+5 · 7mo ago −0.66%α −4.18% · $31.64
  4. T+20 · 7mo ago −9.45%α −18.00% · $28.84
  5. T+60 · 4mo ago +2.04%α −8.42% · $32.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

David Berman, an affiliate of Immunocore Holdings plc, filed a Form 144 to notify intent to sell 25,000 ADRs, representing approximately $796,250 based on current market value. The sale is planned for April 9, 2026, via a cashless exercise and sale through J.P. Morgan Securities LLC.

Key Facts

  • Reporting person: David Berman, identified as an affiliate of the company
  • Number of securities intended for sale: 25,000 ADRs
  • Estimated value of the proposed sale: $796,250 (based on $31.85 per ADR)
  • Planned sale date: April 9, 2026
  • Method of sale: Same-day cashless exercise and sale
  • Broker: J.P. Morgan Securities LLC acting as agent and attorney in fact

Financial Impact

Approximately $796,250 in ADRs to be sold

dilutionshare_countmarket_sentiment

Risk Factors

  • Potential short-term negative sentiment if market interprets sale as lack of confidence
  • Execution risk that sale may occur at a different volume or price than disclosed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001974494-26-000149
Document: 0001974494-26-000149-index.html0001974494-26-000149
Document: 0001974494-26-000149.txt0001974494-26-000149

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026